Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase
Yunsong Tong(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Donald J. Osterling(AbbVie (United States)), Loren Lasko(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Philip J. Merta(AbbVie (United States)), David Maag(AbbVie (United States)), Nirupama B. Soni(AbbVie (United States)), Kenneth D. Bromberg(AbbVie (United States)), Eric F. Johnson(Pfizer (United States)), Amanda M. Olson(Abbott Fund), Maricel Torrent(United States Military Academy), Alan S. Florjancic(AbbVie (United States)), Alexander R. Shoemaker(Abbott Fund)
Cited by 20
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776